TCRFLT3D/Y treatment resulted in undetectable levels of CD34+ FLT3D/Y AML cells in the PB, spleen and BM of all mice engrafted with AML cells from patient 1, compatible with complete elimination of FLT3D/Y AML-propagating cells in vivo through specific TCRFLT3D/Y targeting. The gene discussed is CD34; the disease is acute myeloid leukemia.